Psychemedics logo

PsychemedicsNASDAQ: PMD

Profile

Sector:

Healthcare

Country:

United States

IPO:

22 January 1987

Next earnings report:

28 March 2025

Last dividends:

24 May 2023

Next dividends:

N/A
$13.79 M
-71%vs. 3y high
21%vs. sector
-vs. 3y high
-vs. sector
-26%vs. 3y high
64%vs. sector
-66%vs. 3y high
18%vs. sector

Price

regular market | Wed, 20 Nov 2024 14:30:00 GMT
$2.34-$0.01(-0.43%)
$5.17 M-$535.00 K

Analysts recommendations

Institutional Ownership

PMD Latest News

Psychemedics Corporation Reports Third Quarter 2024 Financial Results
globenewswire.com12 November 2024 Sentiment: POSITIVE

DALLAS, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world's leading provider of hair testing for drugs of abuse, today announced financial results for the third quarter ending September 30, 2024.

Psychemedics Releases First-Ever Education Insights Report: Uncovering Drug Trends in Educational Institutions Through Hair Testing
globenewswire.com26 September 2024 Sentiment: POSITIVE

DALLAS, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a global leader in hair testing for drugs of abuse, is excited to announce the release of its first-ever Education Insights Report.

Psychemedics Corporation Reports Second Quarter 2024 Financial Results
globenewswire.com13 August 2024 Sentiment: POSITIVE

DALLAS, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world's leading provider of hair testing for drugs of abuse, today announced financial results for the second quarter ending June 30, 2024.

What type of business is Psychemedics?

Psychemedics Corporation, together with its subsidiaries, engages in the provision of testing services for the detection of drugs of abuse and other health markers through the analysis of hair samples in the United States and internationally. It offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opioids, such as heroin metabolite, morphine, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium, and Ativan; and nicotine, fentanyl and fentanyl analogs, and alcohol. The company's testing results provide quantitative information that could indicate the approximate amount of drug ingested, as well as historical data that could show a pattern of individual drug use over a longer period-of-time. It offers its services to employers for job applicant and employee testing; and treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use. The company was incorporated in 1986 and is headquartered in Dallas, Texas.

What sector is Psychemedics in?

Psychemedics is in the Healthcare sector

What industry is Psychemedics in?

Psychemedics is in the Diagnostics & Research industry

What country is Psychemedics from?

Psychemedics is headquartered in United States

When did Psychemedics go public?

Psychemedics initial public offering (IPO) was on 22 January 1987

What is Psychemedics website?

https://www.psychemedics.com

Is Psychemedics in the S&P 500?

No, Psychemedics is not included in the S&P 500 index

Is Psychemedics in the NASDAQ 100?

No, Psychemedics is not included in the NASDAQ 100 index

Is Psychemedics in the Dow Jones?

No, Psychemedics is not included in the Dow Jones index

When was Psychemedics the previous earnings report?

No data

When does Psychemedics earnings report?

The next expected earnings date for Psychemedics is 28 March 2025